LifeVantage Reports Earnings Decline as GLP-1 Competition Intensifies

Company highlights early momentum from LoveBiome acquisition and new product launches amid market shifts

Feb. 4, 2026 at 7:23pm

Got story updates? Submit your updates here. ›

LifeVantage (NASDAQ:LFVN) reported a sharp year-over-year decline in revenue and earnings for its fiscal second quarter of 2026 as the company faced intensifying competition in the GLP-1 category and cycled the prior-year launch of its MindBody GLP-1 System. The company recorded a $2.4 million inventory reserve related to MindBody and noted pharmaceutical GLP-1 drugs are becoming more accessible and affordable. However, LifeVantage highlighted early momentum from the LoveBiome acquisition and new product launches as potential growth drivers going forward.

Why it matters

LifeVantage's struggles with its MindBody GLP-1 product in the face of increased competition reflect broader shifts in the nutritional supplements and weight management market. The company's response, including inventory adjustments, cost-cutting measures, and a focus on integrating the LoveBiome acquisition, will be closely watched as it seeks to regain its footing and capitalize on new opportunities.

The details

For the fiscal second quarter, LifeVantage reported net revenue of $48.9 million, down 27.8% from $67.8 million in the year-ago quarter, primarily due to a $16.2 million decrease in MindBody GLP-1 System sales. This decline was partially offset by $4.1 million in revenue from the LoveBiome product line following the October 2025 acquisition. Gross profit margin fell to 74% from 80.5% a year earlier, driven by the inventory reserve and higher shipping and warehouse costs. The company posted GAAP operating income of $0.5 million, down from $3.4 million in the prior-year period, and adjusted net income of $1.9 million, or $0.15 per diluted share, compared with $3.0 million, or $0.22 per diluted share, a year ago.

  • LifeVantage reported fiscal second-quarter 2026 results on February 4, 2026.

The players

LifeVantage Corporation

A publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model.

Steve Fife

Chief Executive Officer of LifeVantage.

Carl Aure

Chief Financial Officer of LifeVantage.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.